The 28th Annual Prostate Cancer Foundation Scientific Retreat report

Miyahira, Andrea K.; Soule, Howard R.

doi:10.1002/pros.24409

Cited by 3 publications

(2 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…XmAb306 (XmAb24306; RO7310729, from Genentech, a member of the Roche Group) is a potency-reduced IL-15/IL-15Rα fusion protein with an XmAb ® bispecific Fc domain ( 96 ). Currently, two Phase I clinical trials to evaluate XmAb24306 as a monotherapy and in combination with atezolizumab or daratumumab in participants with locally advanced/metastatic solid tumors (NCT05243342) or R/R M/M (NCT04250155) are ongoing.…”

Section: Il-15mentioning

confidence: 99%

Engineering cytokines for cancer immunotherapy: a systematic review

Tang

Zhao

2023

Front. Immunol.

View full text Add to dashboard Cite

Cytokines are pivotal mediators of cell communication in the tumor microenvironment. Multiple cytokines are involved in the host antitumor response, but the production and function of these cytokines are usually dysregulated during malignant tumor progression. Considering their clinical potential and the early successful use of cytokines in cancer immunotherapy, such as interferon alpha-2b (IFNα-2b; IntronA®) and IL-2 (Proleukin®), cytokine-based therapeutics have been extensively evaluated in many follow-up clinical trials. Following these initial breakthroughs, however, clinical translation of these natural messenger molecules has been greatly limited owing to their high-degree pleiotropic features and complex biological properties in many cell types. These characteristics, coupled with poor pharmacokinetics (a short half-life), have hampered the delivery of cytokines via systemic administration, particularly because of severe dose-limiting toxicities. New engineering approaches have been developed to widen the therapeutic window, prolong pharmacokinetic effects, enhance tumor targeting and reduce adverse effects, thereby improving therapeutic efficacy. In this review, we focus on the recent progress and competitive landscape in cytokine engineering strategies and preclinical/clinical therapeutics for cancer. In addition, aiming to promote engineered cytokine-based cancer immunotherapy, we present a profound discussion about the feasibility of recently developed methods in clinical medicine translation.

show abstract

Section: Il-15mentioning

confidence: 99%

Engineering cytokines for cancer immunotherapy: a systematic review

Tang

Zhao

2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Notably, the incidence of early menopause is on the rise globally, with numerous countries indicating an upward trend (Miyahira and Soule, 2022). In this research, we focused on South Korea, where pertinent research has detected a decline in the age of menopause.…”

Section: Introductionmentioning

confidence: 99%

Assessing air pollution as a risk factor for early menopause in Korea

Kim,

Min,

Lee

et al. 2024

Preprint

View full text Add to dashboard Cite

Backgrounds Ambient air pollution has become a serious public health issue that affects fertility rates in women worldwide. Therefore, there is a need to evaluate the risk factors associated with menopause to be able to inform women of the associated health risks. Methods We collected data from KHANES (The Korea National Health and Nutrition Examination Survey) between 2010 and 2020, from the Korean Center for Disease Control and Prevention, Ministry of Health and Welfare, and linked it with summary pollution data from AiMS-CREATE (AI-Machine Learning and Statistics Collaborative Research Ensemble for Air Pollution, Temperature, and All Types of Environmental Exposures) from 2002 to 2020. This summary data encapsulates the monthly average air pollution predictions for 226 si-gun-gu (cities, counties, and districts) in Korea. A total of 8,616 participants who had experienced menopause (early menopause: 20–45 years, N = 679; normal menopause: 46–60 years, N = 7,937) between 2002 and 2020 were included in the analysis. We employed survey logistic regression analyses to determine the associations between ambient air pollution and menopause after adjusting for covariates. Results There was an association between particulate matter 2.5 (PM2.5) and early menopause (adjusted odds ratio [aOR]: 1.27, 95% confidence interval [CI]: 1.23–1.32), between particulate matter 10 (PM10) and early menopause (aOR: 1.17, 95% confidence interval [CI]: 1.15–1.20), and between nitrogen dioxide (NO2) and early menopause (aOR: 1.05, 95% confidence interval [CI]: 1.02–1.09). Conclusion Our results are consistent with the proposed hypothesis regarding an association between exposure to ambient air pollution and early menopause. This study provides substantial quantitative evidence that further supports the need for public health interventions to improve air quality, which is a risk in promoting early menopause.

show abstract